Vensana Creates Capital Fund for Breakthrough Medical Devices

Vensana Capital has closed Vensana Capital III with $425 million in committed financing. The fund was oversubscribed at its hard cap with the support of the firm’s existing limited partners alongside select new institutional investors, and it brings Vensana’s total capital under management to approximately $1 billion.

Vensana Capital is a venture capital and growth equity investment firm that partners with medical technology companies in their development and commercial stages. The firm invests across all areas of medtech, with a particular focus on medical device and data science-oriented companies that can potentially create new clinical care standards while also helping to make healthcare more efficient, accessible, and cost-effective.

“We are proud of the progress Vensana has made since launch as we work to build the leading medtech investment and company building platform, and we are beyond grateful for the continued strong support of our limited partners,” Vensana Managing Partner Kirk Nielsen said.

Since its inception, Vensana has been an active medtech investor, with a diversified portfolio of companies advancing first-in-class and best-in-class products. The firm has partnered with more than 20 companies to date and has orchestrated six exits totaling nearly $3 billion in value, including the acquisitions of Artelon, Intact Vascular, Personal Genome Diagnostics, Relievant Medsystems, and Vesper Medical, as well as the initial public offering of CVRx.

Vensana founders and Managing Partners Kirk Nielsen and Justin Klein, M.D., are joined by experienced investors including Partners Amrinder Singh, Cynthia Yee, Greg Banker, and Mike Kramer; venture Partner Bill Hoffman; investment professionals Allison King and Petra Gorombei, Ph.D.; and Partner/Chief Financial Officer Steve Schwen. Vensana’s investment team is further strengthened by an advisory board comprised of medtech entrepreneurs, senior executives, and subject matter experts.

“Our entire team is excited about the opportunity ahead as we continue to partner with entrepreneurs who are transforming healthcare with breakthrough innovations in medical technology,” Dr. Klein added. “We approach each day mindful of the impact that our work has on the missions of our limited partners, on our portfolio companies and their teams, and—most importantly—on our clinician partners and their patients.”

Vensana Capital is a venture capital and growth equity investment firm that partners with entrepreneurs who seek to transform healthcare with breakthrough medtech innovations. Founded in 2019, Vensana is actively investing in development and commercial stage companies across the medtech sector, including medical devices, data science-oriented solutions, life science tools and diagnostics, and tech-enabled services. Vensana’s investment team has partnered with entrepreneurs behind such companies as Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, CVRx, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical.